KR20210150866A - Composition for anti-obesity comprising extract from red bean bud - Google Patents
Composition for anti-obesity comprising extract from red bean bud Download PDFInfo
- Publication number
- KR20210150866A KR20210150866A KR1020200067823A KR20200067823A KR20210150866A KR 20210150866 A KR20210150866 A KR 20210150866A KR 1020200067823 A KR1020200067823 A KR 1020200067823A KR 20200067823 A KR20200067823 A KR 20200067823A KR 20210150866 A KR20210150866 A KR 20210150866A
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- red bean
- pharmaceutical composition
- composition
- azuki
- Prior art date
Links
- 240000001417 Vigna umbellata Species 0.000 title claims abstract description 56
- 235000011453 Vigna umbellata Nutrition 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000000284 extract Substances 0.000 title claims description 48
- 230000003579 anti-obesity Effects 0.000 title description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 43
- 235000020824 obesity Nutrition 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 21
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 20
- 238000009825 accumulation Methods 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract description 10
- SDSUINASRZZKPO-UHFFFAOYSA-N 4,6a,6b,11,11,14b-Hexamethyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8a-({[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid Chemical compound C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)CCC(C2(CCC3C4(C)C(O)=O)C)(C)C1=CCC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O SDSUINASRZZKPO-UHFFFAOYSA-N 0.000 claims description 37
- FXYSHYMHTAACSV-UHFFFAOYSA-N 3-O-<beta-D-glucopyranosyl(1->2)-beta-D-glucuronopyranosyl>azukisapogenol Natural products OCC1(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C(O)=O)CC5C4=CCC3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O FXYSHYMHTAACSV-UHFFFAOYSA-N 0.000 claims description 20
- FXYSHYMHTAACSV-FTHMGGAWSA-N Azukisaponin III Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5C[C@@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2[C@]1(CO)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FXYSHYMHTAACSV-FTHMGGAWSA-N 0.000 claims description 20
- FXYSHYMHTAACSV-LCUOXUEHSA-N Azukisaponin III Natural products O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@](CO)(C)[C@H]3[C@@](C)([C@@H]4[C@](C)([C@@]5(C)C([C@H]6[C@@](C)(CC5)CC[C@](C(=O)O)(C)C6)=CC4)CC3)CC2)O1 FXYSHYMHTAACSV-LCUOXUEHSA-N 0.000 claims description 20
- YRJVEPWBEBAMTP-UHFFFAOYSA-N azukisaponin vi Chemical compound OCC1(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C(=O)OC6C(C(O)C(O)C(COC7C(C(O)C(O)C(CO)O7)O)O6)O)CC5C4=CCC3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O YRJVEPWBEBAMTP-UHFFFAOYSA-N 0.000 claims description 20
- UHNAAKLAPBGWGQ-UHFFFAOYSA-N Azukisaponin VI Natural products CC12CCC(C)(CC1C3=CCC4C5(C)CCC(OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(CO)C5CCC4(C)C3(C)CC2)C(=O)OC8OC(CO)C(O)C(O)C8OC9OC(CO)C(O)C(O)C9O UHNAAKLAPBGWGQ-UHFFFAOYSA-N 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 238000005194 fractionation Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 229930193597 Azukisaponin Natural products 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 abstract description 6
- 150000007949 saponins Chemical class 0.000 abstract description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 description 34
- 210000001789 adipocyte Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- -1 alkali metal salt Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930187719 Soyasaponin Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PPWWANBMWAQXLQ-UHFFFAOYSA-N Azukisaponin I Chemical compound C12CC(C)(C)CC(O)C2(C)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O PPWWANBMWAQXLQ-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940116257 pepper extract Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 235000020991 processed meat Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- JTXVTHCLTOUSSL-UHFFFAOYSA-N sandosaponin a Chemical compound OCC1(C)C2CCC3(C)C4(C)CCC5(C)C(=O)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O JTXVTHCLTOUSSL-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- NARQRJFIZNOSJV-JIHAXZPOSA-N soyasapogenol B 3-O-beta-glucuronide Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(CO)C)C)(C)CC[C@@]1(C)[C@H](O)CC(C[C@H]14)(C)C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O NARQRJFIZNOSJV-JIHAXZPOSA-N 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- KFFJPIQLAPHYBF-UHFFFAOYSA-N Azukisaponin V Natural products COC(=O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CC(O)C6(O)CCC45C)C2(C)CO)C(OC7OC(CO)C(O)C(O)C7OC8OC(C)C(O)C(O)C8O)C(O)C1O KFFJPIQLAPHYBF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000006089 Phaseolus angularis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- UZUYQJHHUUDLDJ-UHFFFAOYSA-N Soyasaponin III Natural products CC1(C)CC(O)C2(C)CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(CO)C5CCC34C)C2C1 UZUYQJHHUUDLDJ-UHFFFAOYSA-N 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000007098 Vigna angularis Species 0.000 description 1
- 235000010711 Vigna angularis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XUZGWYVPUWNJAN-UHFFFAOYSA-N azukisaponin II Natural products COC(=O)C1OC(OC2CCC3(C)C(CCC4(C)C3CC=C5C6CC(C)(C)CC(O)C6(O)CCC45C)C2(C)CO)C(OC7OC(CO)C(O)C(O)C7O)C(O)C1O XUZGWYVPUWNJAN-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical class C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- BMLHAAYMHXIWOH-UHFFFAOYSA-N soyasaponin III methyl ester Natural products OC1C(O)C(C(=O)OC)OC(OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4)C)(C)CC3)(C)CC2)(C)CO)C1OC1OC(CO)C(O)C(O)C1O BMLHAAYMHXIWOH-UHFFFAOYSA-N 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019511 tuna Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 팥순 추출물을 포함하는 비만 억제용 조성물에 관한 것으로, 보다 구체적으로 본 발명은 팥순으로부터 유래된 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 치료용 약학 조성물, 상기 약학 조성물을 이용하여 비만을 치료하는 방법, 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 개선용 식품 조성물 및 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 개선용 사료 조성물에 관한 것이다.The present invention relates to a composition for suppressing obesity comprising a red bean sprout extract, and more particularly, the present invention relates to a preventive or A pharmaceutical composition for treatment, a method for treating obesity using the pharmaceutical composition, a food composition for preventing or ameliorating obesity comprising azuki saponins Ⅲ, Ⅳ, VI or a pharmaceutically acceptable salt thereof, and azuki saponin Ⅲ , IV, VI or relates to a feed composition for preventing or improving obesity comprising a pharmaceutically acceptable salt thereof.
일반적으로, 비만은 일반적으로 체내에 지방 조직이 과다한 상태인 것을 의미하며, 음식물로 섭취한 에너지가 신체활동 등으로 소비한 에너지와 균형을 이루지 못하여 잉여의 에너지가 체지방으로 축적되는 현상이다. 오랜 시간에 걸쳐 에너지 불균형에 의해 체지방이 비정상적으로 많아지면 당뇨병, 고지혈증, 심장병, 뇌졸증, 동맥경화증, 지방간 등의 각종 대사성 질환과 성인병이 유발되며, 이는 서구에서뿐만 아니라 우리나라에서도 심각한 사회문제로 대두되고 있다.In general, obesity refers to a state in which there is an excess of adipose tissue in the body, and is a phenomenon in which energy consumed from food is not in balance with energy consumed through physical activity, and the surplus energy is accumulated as body fat. When body fat increases abnormally due to energy imbalance over a long period of time, various metabolic diseases and adult diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, etc. are induced, which is emerging as a serious social problem not only in the West but also in Korea. .
전 세계적으로 비만 치료제의 개발을 위한 다각적인 측면의 연구가 진행되고 있다. 비만치료용 약물은 크게 지방흡수 억제, 지방 분해 및 열 발생 촉진, 식욕 및 포만감의 조절, 단백질 대사 저해 그리고 음식물의 섭취와 관련된 정서 조절 기전으로 나눌 수 있다. 대표적인 비만 치료제로는 오리스타트(oristat)를 원료로 하여 지방흡수를 억제하는 제니칼™(Xenical™)과 시부트라민(sibutramine)을 주원료로 교감신경계를 자극하여 식욕을 억제시키는 리덕틸™(Reductil™)이 있다. 그러나 제니칼™의 경우 지방변, 복부통증, 구토, 가려움증, 간 손상 등의 부작용이 보고되어 있으며, 리덕틸™의 경우는 두통, 식욕부진, 불면, 변비 등의 부작용뿐만 아니라 심각한 심혈관계 부작용을 일으킨다는 이유로 최근 사용 기준이 강화되는 등의 논란이 일고 있다.Various aspects of research are being conducted worldwide for the development of anti-obesity drugs. Drugs for the treatment of obesity can be broadly divided into fat absorption inhibition, lipolysis and heat generation promotion, appetite and satiety control, protein metabolism inhibition, and emotional regulation related to food intake. Representative anti-obesity treatments include Xenical™, which suppresses fat absorption by using orstat as a raw material, and Reductil™, which suppresses appetite by stimulating the sympathetic nervous system using sibutramine as the main ingredient. . However, in the case of Xenical™, side effects such as fatty stools, abdominal pain, vomiting, itching, and liver damage have been reported. Controversy has arisen over the recent tightening of standards for use.
이러한 비만치료제를 통한 약물요법 이외에도 비만을 예방하고 치료하기 위한 방법으로 음식물의 섭취를 제한하는 식이요법, 에너지 소비를 증가시키는 운동요법이 있으며, 정신요법, 행동요법, 외과요법 등도 실시되고 있다.In addition to drug therapy through these anti-obesity drugs, methods for preventing and treating obesity include diet to limit food intake, exercise therapy to increase energy consumption, and psychotherapy, behavioral therapy, and surgical therapy.
바람직한 비만의 치료 방법으로는 운동을 통한 에너지 소비 촉진과 부작용이 적은 비만치료용 약제를 병행하는 것이 가장 안전하고 효과적인 방법으로 제시되고 있다. 그러나, 비만치료용 약제의 경우, 상기의 제니칼™과 리덕틸™의 예처럼 심각한 부작용들이 보고되고 있으며 안전성에 대한 명확한 신뢰가 뒷받침되지 않고 있는 실정이다. 따라서, 인체에 대해서 항비만의 우수한 효능을 나타내면서도 안전성이 보장되는 물질의 개발이 요구되고 있다.As a preferred treatment method for obesity, it is suggested as the safest and most effective method to promote energy consumption through exercise and to combine drugs for the treatment of obesity with fewer side effects. However, in the case of drugs for the treatment of obesity, serious side effects have been reported as in the examples of Xenical™ and Reductil™ above, and clear trust in safety is not supported. Therefore, there is a demand for the development of a substance that shows excellent anti-obesity efficacy and guarantees safety for the human body.
한편, 팥순은 예전부터 약제로 사용되어 왔고, 비타민, 효소, 엽록소 등의 영양소가 풍부한 것으로 알려져 왔다. 최근에는, 팥에 함유되어있는 우수한 영양성분과 건강 기능성 물질의 다이어트 균형식,체질개선 등에 대한 효과가 알려지면서, 건강 기능성 원료 작물로서의 관심이 증대되고 있으며, 가축사료용 등으로도 우수한 평가를 받고 있다.On the other hand, red bean sprouts have been used as medicines for a long time and have been known to be rich in nutrients such as vitamins, enzymes, and chlorophyll. Recently, as the effects of excellent nutritional components and health functional substances contained in red beans on a balanced diet and body improvement are known, interest as a health functional raw material crop is increasing, and it is also being evaluated excellently for use as livestock feed.
팥순은 팥에 싹을 틔워 약 15cm정도 자란 어린 식물체를 지칭하는데, 대체로 팥을 하루정도 물에 불린 후, 물기를 빼고 적당한 크기의 플라스틱 바구니나 스티로폼에 신문지 등을 깔고 보리를 파종하여, 싹이 날 때까지 종이로 덮어 두었다가 싹이 틔면 제거하고 수분을 유지하면서 7-10일 정도 지나서 l5cm크기가 되면 이를 사용하게 된다. 상기 팥순은 다양한 약리활성을 나타낸다고 알려져 있는데, 예를 들어, 한국등록특허 제10-1177379호에는 산사 추출물, 율무 추출물, 청고추 추출물 및 팥순 추출물을 유효성분으로 함유하는 것을 특징으로 하는 항비만용 조성물이 개시되어 있고, 한국등록특허 제10-1177380호에는 옥수수수염 추출물, 표고버섯 추출물, 청고추 추출물 및 팥순 추출물을 유효성분으로 함유하는 것을 특징으로 하는 항비만용 조성물이 개시되어 있다. 그러나, 이들 혼합추출물에는 비만을 효과적으로 억제하는 성분 뿐만 아니라 비만을 촉진하는 성분 등과 같은 다양한 성분이 포함되어 있을 것으로 예상되고 있으나, 실질적으로 항 비만 효과를 나타내는 성분에 대하여는 규명되어 있지 않다.Red bean sprout refers to a young plant that sprouts and grows to about 15 cm. In general, after soaking the red bean in water for a day or so, drain the water, and spread the newspaper in a plastic basket or Styrofoam of an appropriate size to sow barley. Cover it with paper until it sprouts, remove it when it sprouts, and use it when it reaches a size of l5cm after 7-10 days while maintaining moisture. The red bean sprout is known to exhibit various pharmacological activities. For example, Korean Patent No. 10-1177379 discloses an anti-obesity composition comprising hawthorn extract, adzuki bean extract, green pepper extract and red bean sprout extract as active ingredients. This is disclosed, and Korea Patent No. 10-1177380 discloses an anti-obesity composition comprising corn beard extract, shiitake mushroom extract, green pepper extract and red bean sprout extract as active ingredients. However, these mixed extracts are expected to contain various components such as components that effectively inhibit obesity as well as components that promote obesity, but the components that actually exhibit anti-obesity effects have not been identified.
이러한 배경하에서, 본 발명자들은 팥순 추출물에 포함된 항 비만 효과를 나타내는 유효성분을 규명하고자 예의 연구노력한 결과, 상기 팥순 추출물로부터 분리된 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 실질적인 항 비만 활성을 나타내는 유효성분임을 확인하고, 본 발명을 완성하였다.Under this background, the inventors of the present inventors made intensive research efforts to identify the active ingredients exhibiting the anti-obesity effect contained in the red bean sprout extract. As a result, the azuki saponins Ⅲ, IV or VI isolated from the red bean sprout extract are active ingredients exhibiting substantial anti-obesity activity. was confirmed, and the present invention was completed.
본 발명의 하나의 목적은 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 치료용 약학 조성물을 제공하는 것이다.One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising a azuki saponin III, IV, VI or a pharmaceutically acceptable salt thereof.
본 발명의 다른 목적은 상기 약학 조성물을 이용하여 비만을 치료하는 방법을 제공하는 것이다.Another object of the present invention is to provide a method for treating obesity using the pharmaceutical composition.
본 발명의 또 다른 목적은 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for the prevention or improvement of obesity comprising a azuki saponin III, IV, VI or a pharmaceutically acceptable salt thereof.
본 발명의 또 다른 목적은 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for the prevention or improvement of obesity comprising a azuki saponin III, IV, VI or a pharmaceutically acceptable salt thereof.
상기 목적을 달성하기 위한 본 발명의 일 실시양태는 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염을 포함하는 비만의 예방 또는 치료용 약학 조성물을 제공을 제공한다.One embodiment of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of obesity comprising a azuki saponin III, IV, VI or a pharmaceutically acceptable salt thereof.
본 발명의 용어 "아주키사포닌 Ⅲ(azukisaponin Ⅲ)"란, 팥순 추출물로부터 유래되고, 하기 화학식 1로 표시되는 화합물을 의미한다. 상기 아주키사포닌 Ⅲ는 팥순과 같은 천연 공급원으로부터 분리할 수 있으나 이에 한정되지 않고, 당 업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다. As used herein, the term "azukisaponin Ⅲ (azukisaponin Ⅲ)" refers to a compound derived from red bean sprout extract and represented by the following formula (1). The azuki saponin Ⅲ may be isolated from a natural source such as red bean sprout, but is not limited thereto, and may be chemically synthesized by a method known in the art or a commercially available material may be used.
본 발명의 용어 "아주키사포닌 Ⅳ(azukisaponin Ⅳ)"란, 팥순 추출물로부터 유래되고, 하기 화학식 2로 표시되는 화합물을 의미한다. 상기 아주키사포닌 Ⅳ는 팥순과 같은 천연 공급원으로부터 분리할 수 있으나 이에 한정되지 않고, 당 업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다. As used herein, the term "azukisaponin IV" refers to a compound derived from red bean sprout extract and represented by the following formula (2). The azuki saponin IV may be isolated from a natural source such as red bean sprout, but is not limited thereto, and may be chemically synthesized by a method known in the art or a commercially available material may be used.
본 발명의 용어 "아주키사포닌 Ⅵ(azukisaponin Ⅵ)"란, 팥순 추출물로부터 유래되고, 하기 화학식 3으로 표시되는 화합물을 의미한다. 상기 아주키사포닌 Ⅵ는 팥순과 같은 천연 공급원으로부터 분리할 수 있으나 이에 한정되지 않고, 당 업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다. As used herein, the term “azukisaponin VI” refers to a compound derived from red bean sprout extract and represented by the following formula (3). The azuki saponin VI may be isolated from a natural source such as red bean sprout, but is not limited thereto, and may be chemically synthesized by a method known in the art, or a commercially available material may be used.
상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ는 팥순의 추출물 또는 그의 분획물로부터 분리정제할 수 있으므로, 상기 조성물은 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 팥순 추출물 또는 그의 분획물이 될 수 있다.Since the adzuki saponins Ⅲ, Ⅳ or VI can be separated and purified from an extract or a fraction thereof of red bean sprout, the composition can be an adzuki saponin extract or a fraction thereof containing azuki saponin Ⅲ, IV or VI.
본 발명의 용어 "팥순"이란, 팥에 싹을 틔워 약 15cm정도 자란 어린 식물체를 의미한다. 통상적으로, 상기 팥순은 팥을 하루정도 물에 침지한 후, 수분을 제거하고, 수분의 손실을 방지한 조건에서 파종하여 발아시킨 다음, 7 내지 10일 동안 성장시켜서 수득할 수 있다.As used herein, the term "red bean sprout" refers to a young plant that has sprouted from red beans and grown to about 15 cm. Typically, the red bean sprouts can be obtained by immersing red beans in water for about a day, removing moisture, sown under conditions that prevent moisture loss, germinate, and then grow for 7 to 10 days.
본 발명에 있어서, 상기 팥순은 체지방의 축적을 억제하는 효과를 나타내는 상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ를 포함하며, 상기 팥순의 추출물 또는 그의 분획물을 이용하여 체지방의 축적을 억제할 수 있다.In the present invention, the red bean sprouts contain the azuki saponins Ⅲ, IV or VI, which have the effect of inhibiting the accumulation of body fat, and the red bean sprout extract or its fraction can be used to inhibit the accumulation of body fat.
본 발명의 용어 "추출물"이란, 목적하는 물질을 다양한 용매에 침지한 다음, 상온 또는 가온상태에서 일정시간 동안 추출하여 수득한 액상성분, 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미한다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다.As used herein, the term "extract" refers to a liquid component obtained by immersing a target substance in various solvents and then extracting it at room temperature or in a heated state for a certain period of time, and a solid obtained by removing the solvent from the liquid component. it means. In addition, in addition to the result, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their preparations, and their purified products.
본 발명에 있어서, 상기 추출물은 팥순 추출물을 의미한다. 상기 팥순 추출물은 상기 팥순의 식물전체, 이의 건조물, 가공물 등을 단독으로 또는 조합하여, 물 또는 다양한 유기용매 등으로 추출하여 수득할 수 있다. 이때, 사용되는 유기용매는 지방세포로의 분화를 억제하는 효과를 나타내는 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 추출물을 수득할 수 있는 한, 특별히 이에 제한되지 않으나, 일 예로서, 물, 극성용매 또는 비극성용매가 될 수 있고, 다른 예로서, 물, 탄소수 1 내지 4의 저급 알코올(메탄올, 에탄올, 프로판올 또는 부탄올 등), 이들의 혼합용매 등이 될 수 있으며, 또 다른 예로서, 에탄올 또는 그의 혼합용매를 사용할 수 있다. In the present invention, the extract means red bean sprout extract. The red bean sprout extract can be obtained by extracting the whole plant of the red bean sprout, a dried product thereof, a processed product, etc., alone or in combination, with water or various organic solvents. At this time, the organic solvent used is not particularly limited as long as an extract containing azuki saponins Ⅲ, Ⅳ, or VI, which has an effect of inhibiting differentiation into adipocytes, can be obtained, but as an example, water, a polar solvent Or it may be a non-polar solvent, and as another example, water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol or butanol, etc.), a mixed solvent thereof, etc., as another example, ethanol or its Mixed solvents may be used.
또한, 상기 추출물을 수득하기 위한 방법 역시 체지방의 축적을 억제하는 효과를 나타내는 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 추출물을 수득할 수 있는 한, 특별히 이에 제한되지 않으나, 일 예로서, 상기 팥순의 식물전체, 이의 건조물, 가공물 등을 상기 용매에 침지하고, 10 내지 25℃의 상온에서 추출하는 냉침추출법, 40 내지 100℃로 가열하여 추출하는 가열추출법, 초음파를 가하여 추출하는 초음파추출법, 환류냉각기를 이용한 환류추출법 등의 방법을 사용할 수 있다.In addition, the method for obtaining the extract is also not particularly limited thereto, as long as it can obtain an extract containing azuki saponins III, IV or VI, which exhibits the effect of inhibiting the accumulation of body fat, but as an example, the red bean sprout of the whole plant, its dried product, processed product, etc., immersed in the solvent, and extracted at room temperature of 10 to 25 ° C. Cold extraction method, heating extraction method by heating to 40 to 100 ° C. A method such as a reflux extraction method using
본 발명의 용어 "분획물"이란, 다양한 구성성분을 포함하는 혼합물로부터 특정성분 또는 특정 그룹을 분리하는 분획방법에 의하여 얻어진 결과물을 의미한다.As used herein, the term "fraction" refers to a result obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various components.
본 발명에 있어서, 상기 분획물은 상기 팥순 추출물을 다양한 분획방법에 적용하여 수득하여, 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 분획물로 해석될 수 있다. 상기 추출물의 분획물은 상기 추출물을 다양한 분획방법에 적용하여 수득할 수 있는데, 상기 분획방법은 특별히 이에 제한되지 않으나, 다양한 용매를 처리하여 수행하는 용매 분획법, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 수행하는 한외여과 분획법, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)를 수행하는 크로마토그래피 분획법 등이 될 수 있다. 특히, 상기 용매 분획법에 사용되는 용매는 특별히 이에 제한되지 않으나, 극성 용매 또는 비극성 용매를 사용할 수 있고, 바람직하게는 비극성 용매를 사용할 수 있다. 상기 용매 분획법은 비극성 수준이 높은 용매로부터 낮은 용매를 사용하여 상기 추출물을 순차적으로 분획하는 방식으로 수행될 수 있는데, 예를 들어 헥산 또는 에틸아세테이트를 이용하여 상기 추출물을 순차적으로 분획하는 방법을 사용할 수 있다.In the present invention, the fraction is obtained by applying the red bean sprout extract to various fractionation methods, and can be interpreted as a fraction containing azuki saponins III, IV or VI. The fraction of the extract can be obtained by applying the extract to various fractionation methods, the fractionation method is not particularly limited thereto, but a solvent fractionation method performed by treating various solvents, an ultrafiltration membrane having a constant molecular weight cut-off value It may be an ultrafiltration fractionation method performed by passing through a chromatographic fractionation method, or a chromatographic fractionation method performing various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity). In particular, the solvent used in the solvent fractionation method is not particularly limited thereto, but a polar solvent or a non-polar solvent may be used, and preferably a non-polar solvent may be used. The solvent fractionation method may be performed in a manner of sequentially fractionating the extract from a solvent with a high level of non-polarity to a solvent with a low level, for example, a method of sequentially fractionating the extract using hexane or ethyl acetate. can
본 발명의 용어 "약학적으로 허용되는 염"이란, 양이온과 음이온이 정전기적 인력에 의해 결합하고 있는 물질인 염 중에서도 약제학적으로 사용될 수 있는 형태의 염을 의미하는데, 통상적으로 금속염, 유기 염기와의 염, 무기산과의 염, 유기산과의 염, 염기성 또는 산성 아미노산과의 염 등이 될 수 있다. 예를 들어, 금속염으로는 알칼리 금속염(나트륨염, 칼륨염 등), 알칼리 토금속염(칼슘염, 마그네슘염, 바륨염 등), 알루미늄염 등이 될 수 있고; 유기 염기와의 염으로는 트리에틸아민, 피리딘, 피콜린, 2,6-루티딘, 에탄올아민, 디에탄올아민, 트리에탄올아민, 시클로헥실아민, 디시클로헥실아민, N,N-디벤질에틸렌디아민 등과의 염이 될 수 있으며; 무기산과의 염으로는 염산, 브롬화수소산, 질산, 황산, 인산 등과의 염이 될 수 있고; 유기산과의 염으로는 포름산, 아세트산, 트리플루오로아세트산, 프탈산, 푸마르산, 옥살산, 타르타르산, 말레인산, 시트르산, 숙신산, 메탄술폰산, 벤젠술폰산, p-톨루엔술폰산 등과의 염이 될 수 있으며; 염기성 아미노산과의 염으로는 아르기닌, 라이신, 오르니틴 등과의 염이 될 수 있고; 산성 아미노산과의 염으로는 아스파르트산, 글루탐산 등과의 염이 될 수 있다.As used herein, the term “pharmaceutically acceptable salt” refers to a salt in a form that can be used pharmaceutically among salts in which a cation and anion are bonded by electrostatic attraction, usually with a metal salt, an organic base and salts, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like. For example, the metal salt may be an alkali metal salt (sodium salt, potassium salt, etc.), alkaline earth metal salt (calcium salt, magnesium salt, barium salt, etc.), an aluminum salt or the like; Salts with organic bases include triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine salts with, etc.; salts with inorganic acids may be salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like; Salts with organic acids may be salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like; Salts with basic amino acids may be salts with arginine, lysine, ornithine and the like; The salt with an acidic amino acid may be a salt with aspartic acid, glutamic acid, or the like.
본 발명의 용어 "비만"이란, 일반적으로 체내에 지방조직이 과다한 상태이거나 또는 신체비만지수(체질량지수, Body mass index: 체중(kg)을 신장(m)의 제곱으로 나눈 값)가 25 이상인 경우를 의미한다. 비만증상이 발생한 개체에서는 통상적으로 혈장으로부터 지방세포로 유입된 지방산과 포도당이 에스테르화하여 주로 중성지방의 형태로 축적된다. 본 발명의 목적상 상기 비만증상은 본 발명의 조성물의 투여로 인하여 예방, 경감, 개선 또는 치료될 수 있는 목적질환으로 사용되지만, 특별히 이에 제한되지는 않는다.As used herein, the term "obesity" generally refers to an excessive amount of adipose tissue in the body or when the body mass index (body mass index: weight (kg) divided by the square of height (m)) is 25 or more. means In subjects with obesity symptoms, fatty acids and glucose introduced into adipocytes from plasma are esterified and are mainly accumulated in the form of triglycerides. For the purpose of the present invention, the obesity symptom is used as a target disease that can be prevented, alleviated, improved or treated by administration of the composition of the present invention, but is not particularly limited thereto.
상술한 바와 같이, 본 발명에서 제공하는 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ를 포함하는 팥순 추출물 또는 그의 분획물은 지방세포에 대한 독성을 나타내지 않으면서도, 체지방의 축적을 억제할 수 있으므로, 비만을 예방 또는 치료하는 효과를 나타내는 약학 조성물의 유효성분으로 활용될 수 있다.As described above, the red bean sprout extract or its fraction containing azuki saponins III, IV or VI provided in the present invention can inhibit the accumulation of body fat without showing toxicity to adipocytes. It can be utilized as an active ingredient of a pharmaceutical composition exhibiting a therapeutic effect.
한편, 본 발명의 비만 예방 또는 치료용 약학 조성물은 약학 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 추가로 포함할 수 있는데, 상기 담제는 비자연적인 담체가 될 수 있다. 구체적으로, 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. On the other hand, the pharmaceutical composition for preventing or treating obesity of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition, and the carrier may be an unnatural carrier. Specifically, the pharmaceutical composition is each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories and sterile injection solutions according to conventional methods to be used. can In the present invention, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the extract and its fractions, for example, starch, calcium carbonate, It is prepared by mixing sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to simple diluents such as water and liquid paraffin, which are commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
본 발명의 약학 조성물에 포함된 상기 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염의 함량은 특별히 이에 제한되지 않으나, 최종 조성물 총중량을 기준으로 0.0001 내지 50 중량%, 보다 바람직하게는 0.01 내지 20 중량%의 함량으로 포함될 수 있다. The content of the azuki saponins III, IV, VI or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition of the present invention is not particularly limited thereto, but is based on the total weight of the final composition, 0.0001 to 50% by weight, more preferably It may be included in an amount of 0.01 to 20% by weight.
상기 본 발명의 약학 조성물은 약제학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 용어 "약제학적으로 유효한 양"이란 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적으로 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" of the present invention means to treat or prevent a disease at a reasonable benefit/risk ratio applicable to medical treatment or prevention. It means a sufficient amount, and the effective dose level is the severity of the disease, the drug activity, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion. The duration may be determined according to factors including drugs used in combination or concomitant with the composition of the present invention used and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects.
본 발명의 약학조성물의 투여량은 예를 들어, 본 발명의 약학 조성물을 사람을 포함하는 포유동물에 하루 동안 1 내지 20 ㎎/㎏, 보다 바람직하게는 1 내지 10 ㎎/㎏으로 투여할 수 있고, 본 발명의 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다.The dosage of the pharmaceutical composition of the present invention may be, for example, 1 to 20 mg/kg, more preferably 1 to 10 mg/kg of the pharmaceutical composition of the present invention to mammals including humans per day. , The frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or administered several times by dividing the dose.
본 발명의 다른 실시양태로서, 상기 약학 조성물을 약제학적으로 유효한 양으로 비만이 나타날 가능성이 있거나 또는 나타난 개체에 투여하는 단계를 포함하는 비만을 예방 또는 치료하는 방법을 제공한다.As another embodiment of the present invention, there is provided a method for preventing or treating obesity, comprising administering the pharmaceutical composition to an individual likely to or exhibit obesity in a pharmaceutically effective amount.
본 발명에서 용어 "개체"란 비만이 발병될 가능성이 있거나 또는 발병된 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.In the present invention, the term "individual" includes, without limitation, mammals including rats, livestock, humans, etc., which are likely to develop or have obesity.
본 발명의 비만을 치료하는 방법에 있어서, 상기 약학 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 어떠한 일반적인 경로를 통하여도 투여될 수 있다. 본 발명의 약학 조성물은 특별히 이에 제한되지 않으나, 목적하는 바에 따라 복강내 투여, 정맥내 투여, 근육내 투여, 피하 투여, 피내 투여, 경구 투여, 비내 투여, 폐내 투여, 직장내 투여될 수 있다. 다만, 경구 투여시에는 위산에 의하여 상기 팥순의 추출물 또는 그의 분획물이 변성될 수 있기 때문에 경구용 조성물은 활성 약제를 코팅하거나 위에서의 분해로부터 보호되도록 제형화 되어야 한다. 또한, 상기 조성물은 활성 물질이 표적 세포로 이동할 수 있는 임의의 장치에 의해 투여될 수 있다. In the method of treating obesity of the present invention, the administration route of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, oral administration, intranasal administration, intrapulmonary administration, or rectal administration as desired. However, during oral administration, the extract or its fractions of red bean sprouts may be denatured by gastric acid, so the composition for oral use should be formulated to be coated with an active agent or to be protected from decomposition in the stomach. In addition, the composition may be administered by any device capable of transporting the active agent to a target cell.
본 발명의 또 다른 실시양태는 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염, 상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 팥순 추출물 또는 그의 분획물을 포함하는 비만 예방 또는 개선용 식품 조성물을 제공한다.Another embodiment of the present invention is to prevent or improve obesity, comprising a azuki saponin III, IV, VI or a pharmaceutically acceptable salt thereof, a red bean sprout extract containing the azuki saponin III, IV or VI, or a fraction thereof It provides a food composition for use.
상기 팥순은 오랫동안 식량자원으로서 사용되었고, 그의 추출물은 오랫동안 사용되어 그의 안전성이 입증되었으므로, 이로부터 분리된 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ 역시 상식할 수 있으면서도 비만의 예방 또는 개선을 도모할 수 있는 식품의 형태로 제조되어 섭취할 수 있다. 이때, 상기 식품에 포함되는 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ의 함량은 특별히 이에 제한되지 않으나, 식품 조성물의 총 중량에 대하여 0.01 내지 100 중량%, 보다 바람직하게는 1 내지 80 중량%로 포함될 수 있다. 식품이 음료인 경우에는 100㎖를 기준으로 1 내지 30g, 바람직하게는 3 내지 20g의 비율로 포함될 수 있다. 또한, 상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ는 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.The red bean sprout has been used as a food resource for a long time, and its extract has been used for a long time and its safety has been proven. It can be prepared and consumed in the form of At this time, the content of the azuki saponins III, IV or VI contained in the food is not particularly limited thereto, but may be included in an amount of 0.01 to 100% by weight, more preferably 1 to 80% by weight, based on the total weight of the food composition. . When the food is a beverage, it may be included in a ratio of 1 to 30 g, preferably 3 to 20 g, based on 100 ml. In addition, the azuki saponins Ⅲ, Ⅳ, or Ⅵ may include additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu). In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene ( BHT), etc.), colorant (tar pigment, etc.), color developer (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG sodium glutamate, etc.), sweetener (dulcin, cyclmate, saccharin, sodium, etc.) , flavorings (vanillin, lactones, etc.), bulking agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (flavors), film agents, gum base agents, foam suppressants, solvents, food additives such as improving agents ) can be added. The additive is selected according to the type of food and used in an appropriate amount.
한편, 상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ를 포함하는 식품 조성물을 이용하여 비만 예방 또는 개선용 기능성 식품을 제조할 수 있다.On the other hand, it is possible to prepare a functional food for preventing or improving obesity by using the food composition containing the azuki saponin III, IV or VI.
구체적인 예로, 상기 식품 조성물을 이용하여 비만을 예방 또는 개선시킬 수 있는 가공식품을 제조할 수 있다. 이런 가공식품에는 예들 들어, 과자, 음료, 주류, 발효식품, 통조림, 우유가공식품, 육륙가공식품, 국수 등을 포함한다. 과자는 비스킷, 파이, 케익, 빵, 캔디, 젤리, 껌, 시리얼(곡물푸레이크 등의 식사대용품류 포함) 등을 포함한다. 음료는 음용수, 탄산음료, 기능성이온음료, 쥬스(예들 들어, 사과, 배, 포도, 알로에, 감귤, 복숭아, 당근, 토마토 쥬스 등), 식혜 등을 포함한다. 주류는 청주, 위스키, 소주, 맥주, 양주, 과실주 등을 포함한다. 발효식품은 간장, 된장, 고추장 등을 포함한다. 통조림은 수산물 통조림(예들 들어, 참치, 고등어, 꽁치, 소라 통조림 등), 축산물 통조림(쇠고기, 돼지고기, 닭고기, 칠면조 통조림 등), 농산물 통조림(옥수수, 복숭아, 파일애플 통조림 등)을 포함한다. 우유가공식품은 치즈, 버터, 요구르트 등을 포함한다. 육류가공식품은 돈까스, 비프까스, 치킨까스, 소세지. 탕수육, 너겟류, 너비아니 등을 포함한다. 밀봉포장생면 등의 국수를 포함한다. 이 외에도 상기 조성물은 레토르트식품, 스프류 등에 사용될 수 있다.As a specific example, it is possible to prepare a processed food capable of preventing or improving obesity by using the food composition. Such processed foods include, for example, sweets, beverages, alcoholic beverages, fermented foods, canned foods, milk products, processed meat products, noodles, and the like. Confectionery includes biscuits, pies, cakes, breads, candy, jelly, gum, cereals (including meal substitutes such as cereal flour), and the like. The beverage includes drinking water, carbonated beverage, functional ionized beverage, juice (eg, apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), sikhye, and the like. Alcoholic beverages include sake, whiskey, shochu, beer, Western liquor, fruit wine, and the like. Fermented foods include soy sauce, soybean paste, red pepper paste, and the like. Canned foods include canned seafood (eg, canned tuna, mackerel, saury, conch, etc.), canned livestock products (canned beef, pork, chicken, turkey, etc.), and canned agricultural products (canned corn, peaches, file apples, etc.). Milk products include cheese, butter, yogurt, and the like. Processed meat products include pork cutlet, beef cutlet, chicken cutlet, and sausage. Includes sweet and sour pork, nuggets, and breadcrumbs. Noodles such as sealed packaged raw noodles are included. In addition to this, the composition may be used in retort foods, soups, and the like.
본 발명의 용어 "기능성 식품(functional food)"이란, 특정보건용 식품(food for special health use, FoSHU)와 동일한 용어로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미하는데, 상기 식품은 비만의 예방 또는 개선에 유용한 효과를 얻기 위하여 정제, 캡슐, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.The term "functional food" of the present invention is the same term as food for special health use (FoSHU), and has medical and medical effects processed to efficiently exhibit bioregulatory functions in addition to nutritional supply. It means high food, and the food can be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. to obtain a useful effect in the prevention or improvement of obesity.
본 발명의 또 다른 양태는, 본 발명의 또 다른 실시양태는 아주키사포닌 Ⅲ, Ⅳ, Ⅵ 또는 이들의 약학적으로 허용되는 염, 상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ가 함유된 팥순 추출물 또는 그의 분획물을 포함하는 비만 예방 또는 개선용 사료 조성물을 제공한다. In another aspect of the present invention, another embodiment of the present invention is an adzuki saponin Ⅲ, Ⅳ, VI or a pharmaceutically acceptable salt thereof, a red bean sprout extract containing the azuki saponin Ⅲ, Ⅳ or VI, or its It provides a feed composition for preventing or improving obesity comprising the fraction.
상기 사료 조성물은 사료 첨가제를 포함할 수 있다. 본 발명의 사료첨가제는 사료관리법상의 보조사료에 해당한다.The feed composition may include a feed additive. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act.
본 발명의 용어 "사료"란, 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다.As used herein, the term “feed” may refer to any natural or artificial diet, meal, etc., or a component of the meal, intended for or suitable for being eaten, ingested, and digested by an animal.
상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The type of feed is not particularly limited, and feed commonly used in the art may be used. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton, or food. These may be used alone or in mixture of two or more.
본 발명의 조성물을 이용하면, 비만의 원인이 되는 체지방의 축적을 억제할 수 있으므로, 효과적인 비만의 치료에 널리 활용될 수 있을 것이다.By using the composition of the present invention, since it is possible to suppress the accumulation of body fat that causes obesity, it will be widely used for effective treatment of obesity.
도 1은 팥순 추출물로부터 유래된 18종의 화합물을 검출한 결과를 나타내는 크로마토그램이다.
도 2는 팥순 추출물로부터 분리된 9종의 화합물의 지방세포에 대한 독성을 측정한 결과를 나타내는 그래프이다.
도 3은 팥순 추출물로부터 분리된 9종의 화합물의 체지방 축적 억제효과를 비교한 결과를 나타내는 그래프이다.1 is a chromatogram showing the results of detection of 18 kinds of compounds derived from red bean sprout extract.
2 is a graph showing the results of measuring the toxicity of nine compounds isolated from red bean sprouts extract on adipocytes.
Figure 3 is a graph showing the results of comparing the body fat accumulation inhibitory effect of 9 kinds of compounds isolated from red bean sprout extract.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
실시예 1: 팥순 유래 유효성분의 분리동정Example 1: Separation and identification of active ingredients derived from red bean sprouts
팥을 발아시키고, 5일이 경과한 시점에서 팥삭을 수확하여 동결건조시켰으며, 이를 분말화하여 팥순 분말을 수득하였다.Red beans were germinated, and red bean sprouts were harvested and freeze-dried when 5 days had elapsed, which was then pulverized to obtain red bean sprout powder.
상기 수득한 팥순 분말에 80% 에탄올을 가하여 추출하고, 이를 여과하여 액상성분을 수득하고, 상기 액상성분을 동결건조시켜 팥순 추출물을 수득하였다.80% ethanol was added to the obtained red bean sprout powder for extraction, and this was filtered to obtain a liquid component, and the liquid component was freeze-dried to obtain a red bean sprout extract.
상기 수득한 팥순 추출물을 UPLC(Ultra Performance Liquid Chromatography)에 적용하여 주요한 18종의 화합물을 선별하였다(도 1). 18 major compounds were selected by applying the obtained red bean sprout extract to UPLC (Ultra Performance Liquid Chromatography) (FIG. 1).
도 1은 팥순 추출물로부터 유래된 18종의 화합물을 검출한 결과를 나타내는 크로마토그램이다.1 is a chromatogram showing the results of detection of 18 compounds derived from red bean sprout extract.
상기 도 1에서 보듯이, 총 18종의 화합물을 검출하였으나, 실험적으로 순수분리된 화합물은 9종에 불과하였으므로, 이하의 실시예에서는, 순수분리된 9종의 화합물을 사용하였다.As shown in FIG. 1 , a total of 18 compounds were detected, but only 9 compounds were experimentally isolated from pure water, so in the following examples, 9 types of purely isolated compounds were used.
우선, 상기 순수분리된 9종의 화합물을 NMR(Nuclear Magnetic Resonance) 분석기기에 적용하여, 각 화합물을 동정하였다(표 1). First, the 9 kinds of pure separated compounds were applied to an NMR (Nuclear Magnetic Resonance) analyzer to identify each compound (Table 1).
2
3
4
5
6
7
8
9One
2
3
4
5
6
7
8
9
Azukisaponin Ⅱ
Azukisaponin Ⅲ
Azukisaponin Ⅳ
Azukisaponin Ⅴ
Azukisaponin Ⅵ
Soyasaponin Bd
Soyasaponin Bc
Soyasapogenol B 3-O-β-glucuronideAzukisaponin I
Azukisaponin II
Azukisaponin III
Azukisaponin IV
Azukisaponin Ⅴ
Azukisaponin Ⅵ
Soyasaponin Bd
Soyasaponin Bc
Soyasapogenol B 3-O-β-glucuronide
실시예 2: 지방세포에 대한 각 화합물의 세포독성 평가Example 2: Evaluation of cytotoxicity of each compound on adipocytes
지방전구세포인 3T3-L1 세포는 BCS(Bovine Calf Serum)를 포함하는 배지에서 계대배양할 수 있고, 적절한 분화유도물질(FBS(feral bovine serum), IBMX(3-isobutyl-methylxanthine), dexanmethasone, 인슐린 등)의 첨가에 의하여 지방세포로 분화될 수 있는 것으로 알려져 있다. 상기 분화유도물질을 처리하면, 지방 전사인자(C/EBPα, C/EBPβ, C/EBPγ, PPARγ 등)가 발현되고, 지방세포로 분화가 완료되면, 지방 전사인자(C/EBPα, PPARγ 등)와 지방세포 특이적 유전자(aP2, Adipsin 등)가 발현된다고 알려져 있다.3T3-L1 cells, which are pre-adipocytes, can be subcultured in a medium containing BCS (Bovine Calf Serum), and appropriate differentiation inducers (FBS (feral bovine serum), IBMX (3-isobutyl-methylxanthine), dexanmethasone, insulin). etc.), it is known that it can be differentiated into adipocytes. When the differentiation inducer is treated, fat transcription factors (C/EBPa, C/EBPβ, C/EBPγ, PPARγ, etc.) are expressed, and when differentiation into adipocytes is completed, fat transcription factors (C/EBPa, PPARγ, etc.) and adipocyte-specific genes (aP2, Adipsin, etc.) are known to be expressed.
본 발명자들은 상기 3T3-L1 세포가 지방세포로 분화될 때, 상기 실시예 1에서 분리한 9종의 화합물이 미치는 효과를 평가하고자 하였다.The present inventors tried to evaluate the effect of the 9 types of compounds isolated in Example 1 when the 3T3-L1 cells are differentiated into adipocytes.
구체적으로, 지방전구세포인 3T3-L1 세포(Korean Cell Line Bank, Korea)를 구입하여 10% FBS(fetal bovine serum) 및 1% 항생제(antibiotics; 페니실린 100 U/ml 및 스테렙토마이신 0.1 mg/ml)을 첨가한 DMEM(Dulbecco's modified eagle medium) 배지를 이용하여 37℃에서 5% CO2(95% air) 조건 하에 배양하였다.Specifically, 3T3-L1 cells, which are preadipocytes, were purchased (Korean Cell Line Bank, Korea), and 10% FBS (fetal bovine serum) and 1% antibiotics; penicillin 100 U/ml and stereptomycin 0.1 mg/ml ) was added to DMEM (Dulbecco's modified eagle medium) medium and cultured at 37° C. under 5% CO 2 (95% air) conditions.
상기 배양된 3T3-L1 세포에 상기 실시예 1에서 분리한 9종의 화합물을 50 μM의 농도로 각각 처리하고, 분화유도물질(FBS, IBMX, dexanmethasone 및 인슐린)이 포함된 배지에서 72시간 동안 배양하여 지방세포로 분화시켰으며, MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 용액을 가하고, 37℃에서 4시간 동안 반응시킨 다음, DMSO를 가하여 상기 세포에서 생성된 포르마잔을 용해시킨 후, 570 nm에서 흡광도를 측정하는 방식으로 세포생존율을 측정하였다(도 2). 이때, 대조군으로는 루토나린 또는 사포나린에 해당하는 물질을 처리하지 않은 지방세포를 사용하고, 비교군으로는 CLA를 동일한 농도로 처리한 지방세포를 사용하였다.The cultured 3T3-L1 cells were treated with each of the nine compounds isolated in Example 1 at a concentration of 50 μM, and cultured in a medium containing differentiation inducing substances (FBS, IBMX, dexanmethasone and insulin) for 72 hours. was differentiated into adipocytes, and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) solution was added, followed by reaction at 37° C. for 4 hours, and then DMSO was added to the cells. After dissolving the formazan produced in , the cell viability was measured by measuring the absorbance at 570 nm (FIG. 2). In this case, as a control group, adipocytes that were not treated with substances corresponding to rutonarin or saponarin were used, and as a control group, adipocytes treated with CLA at the same concentration were used.
도 2는 팥순 추출물로부터 분리된 9종의 화합물의 지방세포에 대한 독성을 측정한 결과를 나타내는 그래프이다.2 is a graph showing the results of measuring the toxicity of nine compounds isolated from red bean sprouts extract on adipocytes.
도 2에서 보듯이, 팥순 추출물로부터 분리된 9종의 화합물은 정도의 차이는 있을 뿐, 지방세포로의 분화과정에서 세포생존율을 감소시키지 않았고, 일부 화합물은 오히려 지방세포의 수준을 증가시킬 수 있음을 확인하였다.As shown in FIG. 2 , the 9 types of compounds isolated from the red bean sprout extract did not reduce the cell viability in the process of differentiation into adipocytes with only a difference in degree, and some compounds could rather increase the level of adipocytes. Confirmed.
실시예 3: 각 화합물의 체지방 축적 억제효과Example 3: Inhibition of body fat accumulation of each compound
체지방의 축적 억제효과를 검정하기 위해, 상기 실시예 2의 방법을 변형시켜서 수행하였다.In order to test the effect of inhibiting the accumulation of body fat, the method of Example 2 was modified and performed.
대략적으로, 지방전구세포인 3T3-L1 세포는 BCS(Bovine Calf Serum)를 포함하는 배지에서 계대배양 하였고, 팥순 추출물 유래 분리된 9종의 화합물을 각각 50 μM로 처리하여 함께 분화시킨 세포에 5% 포름알데히드(Formaldehyde)를 처리하여 약 30분간 실온에서 고정하였다. 고정한 세포에 Oil-Red O 염색시약을 20분간 처리한 뒤 증류수로 충분히 여러번 세척하고 아이소프로판올(Isopropanol)을 투입하여 염색된 세포지방구에서 Oil-Red O 염색약을 추출하여 490nm에서 흡광도를 측정하였다(도 3). 이때, 측정된 흡광도의 수준이 낮을 수록 체지방 축적 억제효과가 우수하다고 판정하였다.Roughly, 3T3-L1 cells, which are pre-adipocytes, were subcultured in a medium containing BCS (Bovine Calf Serum), and 9 types of compounds derived from red bean sprout extract were treated with 50 μM each of 5% to the co-differentiated cells. It was treated with formaldehyde and fixed at room temperature for about 30 minutes. After treating the fixed cells with Oil-Red O staining reagent for 20 minutes, washing them sufficiently with distilled water several times, adding isopropanol, and extracting Oil-Red O dye from the stained cell fat cells, and measuring the absorbance at 490 nm ( 3). At this time, it was determined that the lower the measured absorbance level, the better the body fat accumulation inhibitory effect.
도 3은 팥순 추출물로부터 분리된 9종의 화합물의 체지방 축적 억제효과를 비교한 결과를 나타내는 그래프이다.3 is a graph showing the results of comparing the body fat accumulation inhibitory effect of 9 types of compounds isolated from red bean sprout extract.
도 3에서 보듯이, 팥순 추출물로부터 분리된 9종의 화합물 중에서 Azukisaponin Ⅳ(화합물 4)가 가장 우수한 체지방 축적 억제효과를 나타내었고, Azukisaponin Ⅵ(화합물 6) 및 Azukisaponin Ⅲ(화합물 3) 역시 우수한 체지방 축적 억제효과를 나타냄을 확인하였다.As shown in FIG. 3 , among the nine compounds isolated from red bean sprout extract, Azukisaponin IV (Compound 4) showed the most excellent body fat accumulation inhibitory effect, and Azukisaponin VI (Compound 6) and Azukisaponin III (Compound 3) also exhibited excellent body fat accumulation. It was confirmed that it exhibits an inhibitory effect.
한편, 화합물 7(Soyasaponin Bd) 및 8(Soyasaponin Bc) 역시 Azukisaponin Ⅵ(화합물 6)과 유사한 수준의 체지방 축적 억제효과를 나타내었고, 화합물 9(Soyasapogenol B 3-O-β-glucuronide)는 Azukisaponin Ⅲ(화합물 3)와 유사한 수준의 체지방 축적 억제효과를 나타내었으나, 상기 화합물 7 내지 9는 소야사포닌 계열의 화합물로서 아주키사포닌 계열의 화합물(화합물 3, 4, 6)과는 상이한 생체내 작용기작을 나타낼 것으로 분석되었다.On the other hand, compounds 7 (Soyasaponin Bd) and 8 (Soyasaponin Bc) also showed a similar level of body fat accumulation inhibitory effect as Azukisaponin VI (Compound 6), and Compound 9 (Soyasapogenol B 3-O-β-glucuronide) was Azukisaponin Ⅲ ( Although it exhibited a similar level of body fat accumulation inhibitory effect as compound 3), the
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention, rather than the above detailed description, all changes or modifications derived from the meaning and scope of the following claims and their equivalents.
Claims (9)
A pharmaceutical composition for the prevention or treatment of obesity, comprising a azuki saponin Ⅲ, Ⅳ, VI or a pharmaceutically acceptable salt thereof.
상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ는 체지방의 축적을 억제하는 효과를 나타내는 것인, 약학 조성물.
According to claim 1,
The azuki saponin Ⅲ, Ⅳ or VI will exhibit the effect of inhibiting the accumulation of body fat, a pharmaceutical composition.
상기 아주키사포닌 Ⅲ, Ⅳ 또는 Ⅵ는 팥순 추출물 또는 그의 분획물로부터 분리된 것인, 약학 조성물.
According to claim 1,
The azuki saponins Ⅲ, Ⅳ or Ⅵ are isolated from red bean sprout extract or a fraction thereof, a pharmaceutical composition.
상기 팥순 추출물은 팥순을 물, 탄소수 1 내지 4의 저급 알코올 및 이들의 혼합용매로 구성된 군으로부터 선택되는 용매로 추출하여 수득한 것인, 약학 조성물.
4. The method of claim 3,
The red bean sprout extract is a pharmaceutical composition obtained by extracting the red bean sprout with a solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms, and a mixed solvent thereof.
상기 분획물은 상기 팥순 추출물을 용매 분획법, 한외여과 분획법, 크로마토그래피 분획법 및 이들의 조합으로 구성된 군으로부터 선택되는 방법에 적용하여 수득한 분획물인 것인, 약학 조성물.
4. The method of claim 3,
The fraction is a fraction obtained by subjecting the red bean sprout extract to a method selected from the group consisting of solvent fractionation method, ultrafiltration fractionation method, chromatographic fractionation method, and combinations thereof, a pharmaceutical composition.
상기 약학 조성물은 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함하는 것인, 약학 조성물.
According to claim 1,
The pharmaceutical composition will further comprise a pharmaceutically acceptable carrier, excipient or diluent.
A method for preventing or treating obesity, comprising administering the pharmaceutical composition of any one of claims 1 to 6 to an individual likely to or exhibit obesity in a pharmaceutically effective amount.
A food composition for preventing or improving obesity, comprising a azuki saponin Ⅲ, Ⅳ, VI or a pharmaceutically acceptable salt thereof.
A feed composition for preventing or improving obesity, comprising a azuki saponin Ⅲ, Ⅳ, VI or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200067823A KR20210150866A (en) | 2020-06-04 | 2020-06-04 | Composition for anti-obesity comprising extract from red bean bud |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200067823A KR20210150866A (en) | 2020-06-04 | 2020-06-04 | Composition for anti-obesity comprising extract from red bean bud |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210150866A true KR20210150866A (en) | 2021-12-13 |
Family
ID=78832053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200067823A KR20210150866A (en) | 2020-06-04 | 2020-06-04 | Composition for anti-obesity comprising extract from red bean bud |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210150866A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102606384B1 (en) * | 2022-12-12 | 2023-11-29 | 대한민국 | Composition for anti-obesity comprising a compound derived from red bean bud |
-
2020
- 2020-06-04 KR KR1020200067823A patent/KR20210150866A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102606384B1 (en) * | 2022-12-12 | 2023-11-29 | 대한민국 | Composition for anti-obesity comprising a compound derived from red bean bud |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6818018B2 (en) | Composition for prevention, improvement or treatment of muscle diseases or improvement of muscle function | |
KR101645464B1 (en) | Composition for anti-obesity comprising extract from young barley leaves | |
KR101594972B1 (en) | Pharmaceutical composition for treating hypertension comprising extract from young barley leaves | |
KR101621447B1 (en) | Pharmaceutical composition for anti-obesity comprising complex extracts including Saururi chinensis Baill. extract, Curcumae Longae Rhizoma extract and Polygalae Radix extract | |
KR20210150866A (en) | Composition for anti-obesity comprising extract from red bean bud | |
KR20130083427A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
KR102152947B1 (en) | Compositions for Preventing, Improving or Treating Non-Alcoholic Fatty Liver Disease Comprising Combined Extracts of Peach Blossom and Lotus Leaf | |
KR20220147428A (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
KR101886299B1 (en) | Compositions for Preventing, Improving or Treating Obesity and Metabolic Diseases Comprising Combined Extracts of Peach Blossom and Lotus Leaf | |
KR101257329B1 (en) | Composition for treating or preventing obesity containing stichpus japonicus extract | |
KR101972657B1 (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis | |
KR102606384B1 (en) | Composition for anti-obesity comprising a compound derived from red bean bud | |
KR101830480B1 (en) | Pharmaceutical composition for preventing or treating hypertriglyceridemia comprising methyl linolenate | |
KR102623117B1 (en) | Composition for prevention and treating obesity of 2,4,6-tripehenyl-1-hexene | |
KR102152959B1 (en) | Compositions for Preventing, Improving or Treating Non-Alcoholic Fatty Liver Disease Comprising Combined Extracts of Peach Blossom and Water Chestnut | |
KR102380295B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of oat | |
KR102200260B1 (en) | Manufacturing method of Allium senescens and Sanguisorba officinalis L. and Pharmaceutical Composition and composition for improving metabolic syndrome induced from obesity and obesity comprising the extract as an active ingredient | |
KR102281039B1 (en) | Pharmaceutical composition for the improvement or treatment of obesity or obesity-induced metabolic syndrome comprising cockcomb extract as an active ingredient | |
US11864575B2 (en) | Composition comprising low temperature water extract of hibiscus manihot for anti-obesity | |
KR101338532B1 (en) | Composition for preventing or treating colon cancer containing extract of sea cucumber | |
WO2022098153A1 (en) | Novel use of bojungikgitang for preventing or treating cachexia | |
KR20210050085A (en) | Pharmaceutical composition comprising mixed extract of Gynostemma phetaphyllum and black radish | |
KR101996184B1 (en) | Adjuvant of anti-cancer agent comprising and an extract of Allium sativum L. for treating and preventing cachexia | |
KR101886314B1 (en) | Compositions for Preventing, Improving or Treating Obesity and Metabolic Diseases Comprising Combined Extracts of Peach Blossom and Water Chestnut | |
JP6047545B2 (en) | A pharmaceutical composition for preventing or treating obesity, comprising a combined extract of Sangpaxo, Kyo-Oh and Onji |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |